AMELIE
- Company typePrivate
- Founded2020
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
AMELIE firmographics
Firmographics- Name
- AMELIE
- Legal name
- AMELIE (Anchored Muscle cELIs for IncontinencE)
- Website
- https://amelie-project.eu
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
AMELIE industry classification
Industry- Product category
- Regenerative Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where AMELIE is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
AMELIE business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- EU Horizon 2020 Funding: AMELIE is a 5-year collaborative research project funded by the European Union's Horizon 2020 Framework Programme under grant agreement No 874807. The project is currently in the research and development phase with no commercial revenue.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
AMELIE product offering
Product offeringCore offering
AMELIE is developing a regenerative cell therapy that uses a patient's own skeletal muscle-derived cells (ASMDC) attached to biodegradable microcarriers for implantation to repair damaged sphincter muscle in patients suffering from faecal incontinence. The therapy is classified as a combined advanced therapy medicinal product (ATMP) and is currently in pan-European clinical trials, with the first six patients treated by July 2026 across two UK sites.
Product overview
AMELIE (Anchored Muscle cELIs for IncontinencE) is a single, unified regenerative cell therapy product. The therapy involves autologous skeletal muscle-derived cells attached to implantable biodegradable microcarriers, classified as a combined advanced therapy medicinal product (ATMP). The approach enables cells to be implanted while remaining attached to a supportive scaffold, improving cell delivery and engraftment to treat faecal incontinence caused by sphincter injury from childbirth, surgery, or trauma.
Differentiator
Problem solved
Functional benefit
Products and services
- AMELIE Autologous Skeletal Muscle-Derived Cell Therapy A regenerative cell therapy using a patient's own (autologous) skeletal muscle-derived cells attached to biodegradable microcarriers for implantation to restore sphincter muscle function in patients with faecal incontinence caused by childbirth injury, surgery, or trauma. Classified as a combined advanced therapy medicinal product (ATMP).
Quantifiable outcome
- Clinical trial evaluating reduction in frequency of faecal incontinence episodes through pan-European randomised, double-blind trial
- +1 more outcomes
Companies that use AMELIE
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
AMELIE technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
AMELIE partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, major and supporting.
- University College London (UCL)coreProject coordinator. Led by Professor Richard Day, Professor of Regenerative Medicine Technology at UCL. Provides overall project leadership and coordination of the 13-partner consortium across 9 countries.
- Bowel Research UKcoreUK's leading specialist bowel cancer and bowel cancer research charity. Designated lead for Dissemination and Communication of research activities. Conducts patient and public involvement activities, survey research, and awareness campaigns.
- Queen Mary UniversitymajorAcademic partner in the 13-organisation consortium contributing research expertise.
- Aarhus UniversitymajorDanish academic partner contributing to the multidisciplinary consortium research.
- Aarhus HospitalmajorDanish hospital partner providing clinical research expertise and potentially clinical trial sites.
- PNO InnovationmajorInnovation consultancy partner providing expertise in translational development and commercialisation strategy.
- The Royal London HospitalcoreClinical trial site where first patients have been treated using the AMELIE regenerative therapy.
- University Hospital of WalescoreClinical trial site where patients are being treated using the AMELIE regenerative therapy.
- World Federation of Incontinence and Pelvic Problems (WFIPP)majorPartner in survey research and public awareness campaigns. Supports World Continence Week initiatives and patient advocacy.
- MASIC FoundationsupportingUK charity representing women with obstetric injuries (injuries during childbirth). Disseminates surveys and supports patient recruitment to clinical trials.
- Associació per la Incontinència Anal (ASIA)supportingEuropean patient advocacy organisation contributing to survey research on faecal incontinence.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
AMELIE competitors and assessment
Company assessmentEmerging players
- Pluristem Therapeutics: Cell-therapy developer using placenta-derived adherent stromal cells for muscle injury and inflammatory indications. Comparable to AMELIE as a regenerative cell-therapy platform with musculoskeletal applications, though using allogeneic rather than autologous cells.
- Capricor Therapeutics: Clinical-stage biotech developing cell therapy (CAP-1002, cardiosphere-derived cells) for cardiac and musculoskeletal indications. Comparable to AMELIE in regenerative cell therapy platform approach and ATMP designation, though focused on cardiac rather than sphincter applications.
- Organogenesis: Commercial regenerative medicine company selling living-cell-based skin and wound-care therapies (Apligraf, Dermagraft). Comparable to AMELIE in scaffold-based living-cell therapy manufacturing and FDA/ATMP-style approval pathway, though focused on dermal rather than muscular indications.
- Axonics: Commercial-stage developer of sacral neuromodulation systems (SNM) for faecal and urinary incontinence. Direct competitor to AMELIE in the same indication via a different modality (electrical neuromodulation vs. regenerative cell therapy), and a likely benchmark for physician adoption in the same patient population.
Direct peers
- Mesoblast: Clinical-stage cell therapy company developing mesenchymal lineage cell therapies for inflammatory and musculoskeletal conditions. Comparable to AMELIE in regenerative cell therapy modality and ATMP/Biologics regulatory pathway, though focused on allogeneic rather than autologous cells.
- TiGenix (acquired by Takeda): Was the leading European cell therapy company; its lead product darvadstrocel (Cx601) treated complex perianal fistulas in Crohn's disease—a near-adjacent indication to AMELIE's faecal incontinence. Acquired by Takeda in 2018 and represents the most relevant historical commercial template for AMELIE.
- Avita Medical: Developer of RECELL, an autologous cell-based regenerative therapy for skin wounds and burns. Closely comparable to AMELIE in using patient-derived cells attached to a delivery scaffold and pursuing ATMP-style regulatory pathways for regenerative indications.
- Vericel: Commercial-stage autologous cell therapy developer (MACI for cartilage repair, Epicel for burns). Vericel is the most directly comparable US-listed autologous cell-therapy business model, sharing AMELIE's regulatory pathway (ATMP/Biologics) and patient-derived cell manufacturing approach.
Broad incumbents
- Medtronic: Sells InterStim sacral nerve stimulation therapy, the incumbent minimally-invasive treatment for faecal incontinence. Represents AMELIE's primary competitive alternative in the clinic; large-cap incumbent with established reimbursement and physician adoption.
- Cook Myosite: Cook Medical's regenerative medicine division developing autologous cell therapies for urinary and faecal incontinence. Directly comparable to AMELIE's sphincter-regeneration therapeutic concept and is one of AMELIE's closest functional competitors despite broader corporate portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
AMELIE social profiles
Digital presenceAMELIE financial estimates
Financial estimateRevenue estimate
Valuation estimate
AMELIE leadership team
Management profileNumber of profiles
Profiles8 records
AMELIE funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AMELIE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AMELIE
What does AMELIE do?
AMELIE is developing a regenerative cell therapy that uses a patient's own skeletal muscle-derived cells (ASMDC) attached to biodegradable microcarriers for implantation to repair damaged sphincter muscle in patients suffering from faecal incontinence. The therapy is classified as a combined advanced therapy medicinal product (ATMP) and is currently in pan-European clinical trials, with the first six patients treated by July 2026 across two UK sites.
Is AMELIE a public or private company?
AMELIE is a private company. It is classified as unknown and is currently operating.
When was AMELIE founded?
AMELIE was founded in 2020. It employs 11 to 50 people.
Where is AMELIE based?
AMELIE is headquartered in London, United Kingdom, in the Europe region.
How does AMELIE make money?
One revenue line is on record: EU Horizon 2020 Funding.
Who are AMELIE's main competitors?
Emerging players on record are Pluristem Therapeutics, Capricor Therapeutics, Organogenesis and Axonics. Direct peers are Mesoblast, TiGenix (acquired by Takeda), Avita Medical and Vericel. Broad incumbents are Medtronic and Cook Myosite.
Does AMELIE have an API?
No public API is recorded for AMELIE.
What industry is AMELIE in?
AMELIE's product category is Regenerative Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.